Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single and multiple ascending dose study to evaluate the safety, tolerability and PK of ALKS 2680 in healthy subjects and subjects with hypersomnia

Next Previous
Trial Profile

A single and multiple ascending dose study to evaluate the safety, tolerability and PK of ALKS 2680 in healthy subjects and subjects with hypersomnia

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALKS 2680 (Primary)
  • Indications Idiopathic hypersomnia; Narcolepsy
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Alkermes

Most Recent Events

  • 29 May 2025 According to an Alkermes plc media release, the company will present data from this trial at the SLEEP 2025, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 8-11, 2025 in Seattle.
  • 07 Nov 2024 According to an Alkermes plc media release, the company presented data from this study at 37th Annual Psych Congress (Psych Congress), which took place Oct. 29-Nov. 2, 2024 in Boston
  • 23 Sep 2024 According to an Alkermes plc media release, company plans to present clinical data from this study at the European Sleep Research Society's (ESRS) 27th Congress, Sleep Europe 2024, taking place Sept. 24-27, 2024 in Seville, Spain.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top